CGTLive’s Weekly Rewind – January 6, 2023

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Homology Medicines Anticipating Gene Therapy Data Updates in PKU, Hunter Syndrome

Initial data from the trials of HMI-103 and HMI-203 are expected in 2023.

2. Cilta-cel Garners More Positive Data in Early and Late Relapsed Multiple Myeloma Treatment

Ying Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.

3. Liso-Cel Confirms Superiority Over SOC in Second-Line LBCL

Second-line lisocabtagene maraleucel reduced the risk of an event occurring by 64.4% compared with standard-of-care chemoimmunotherapy induction and autologous stem cell transplantation.

4. Jakub Svoboda, MD, on Promising Efficacy With huCART19-IL18 in NHL, CHL

The associate professor of medicine from University of Pennsylvania discussed updated data on huCART19-IL18 presented at the ASH 2022 meeting.

5. 2022 Year in Review: Top News and Insights in Cell Therapy

Review some of our most-viewed coverage of advancements in cell therapies, including study data and clinical trial updates.